UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro

PloS one, 2018-04, Vol.13 (4), p.e0195316-e0195316

2018

Volltextzugriff (PDF)

Therapeutic Effects of Anti‐FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia

Journal of bone and mineral research, 2009-11, Vol.24 (11), p.1879-1888

2009

Volltextzugriff (PDF)

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study

Clinical and experimental nephrology, 2020-07, Vol.24 (7), p.630-637

2020

Volltextzugriff (PDF)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study

PloS one, 2019-05, Vol.14 (5), p.e0216399-e0216399

2019

Volltextzugriff (PDF)

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism

Kidney international, 2005-02, Vol.67 (2), p.467-476

2005

Volltextzugriff (PDF)

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism

BMC nephrology, 2020-10, Vol.21 (1), p.432-432, Article 432

2020

Volltextzugriff (PDF)

The dihydropyridine calcium channel blocker benidipine prevents lysophosphatidylcholine-induced endothelial dysfunction in rat aorta

Journal of biomedical science, 2009-06, Vol.16 (1), p.57-57

2009

Volltextzugriff (PDF)

Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats

Journal of the American Society of Nephrology, 2000-05, Vol.11 (5), p.903-911

2000

Volltextzugriff (PDF)

Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism

European journal of endocrinology, 2005-10, Vol.153 (4), p.587

2005

Volltextzugriff (PDF)

Cinacalcet suppresses calcification of the aorta and heart in uremic rats

Kidney international, 2008-11, Vol.74 (10), p.1270-1277

2008

Volltextzugriff (PDF)

A novel calcimimetic agent, evocalcet

PloS one, 2018-04, Vol.13 (4), p.e0195316

2018

Volltextzugriff (PDF)

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

Clinical and experimental nephrology, 2019-03, Vol.23 (3), p.435-435

2019

Volltextzugriff (PDF)

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor

The Journal of clinical investigation, 1997-12, Vol.100 (12), p.2977-2983

1997

Volltextzugriff (PDF)

Control of parathyroid cell growth by calcimimetics

Nephrology, dialysis, transplantation, 2003-06, Vol.18 (suppl-3), p.iii13-iii17

2003

Volltextzugriff (PDF)

Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism

Kidney international, 2000-01, Vol.57 (1), p.50-58

2000

Volltextzugriff (PDF)

Pharmacological properties of the calcimimetic compound NPS R-568 in vitro and in vivo

Clinical and experimental nephrology, 2000-12, Vol.4 (4), p.293-299

2000

Volltextzugriff (PDF)

S38-5 Calcium receptor agonist (calcimimetics)：therapeutic potential in hyperparathyroidism

Journal of Pharmacological Sciences, 2004, Vol.94 (suppl.1), p.59-59

2004

Volltextzugriff (PDF)

NPS R-568 halts or reverses osteitis fibrosa in uremic rats

Kidney international, 1998-02, Vol.53 (2), p.448-453

1998

Volltextzugriff (PDF)

Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Commentary

Kidney international, 2008, Vol.74 (10)

2008

Volltextzugriff (PDF)

Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency

Nephrology, dialysis, transplantation, 2003-10, Vol.18 (10), p.2014-2023

2003

Volltextzugriff (PDF)

Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels

Journal of bone and mineral metabolism, 2006-07, Vol.24 (4), p.300-306

2006

Volltextzugriff (PDF)

P2L-P13-2 Calcimimetics(cinacalcet HCI)suppress aortic and heart calcification in uremic rats

Journal of Pharmacological Sciences, 2009, Vol.109 (suppl.2), p.241-241

2009

Volltextzugriff (PDF)

Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency

Nephrology, dialysis, transplantation, 2006-03, Vol.21 (3), p.634-643

2006

Volltextzugriff (PDF)

Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA®)

Folia Pharmacologica Japonica, 2008, Vol.132(5), pp.301-308

2008

Volltextzugriff (PDF)

P3L-20 Effect of manipulating serum phosphorus with sevelamer hydrochloride, a phosphate binder, on circulating parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) levels in rats with chronic renal insufficiency

Journal of Pharmacological Sciences, 2006, Vol.100 (suppl.2), p.267-267

2006

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(49)
Buchkapitel
(1)

Sprache

Englisch
(40)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro

Therapeutic Effects of Anti‐FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism

The dihydropyridine calcium channel blocker benidipine prevents lysophosphatidylcholine-induced endothelial dysfunction in rat aorta

Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats

Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism

Cinacalcet suppresses calcification of the aorta and heart in uremic rats

A novel calcimimetic agent, evocalcet

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor

Control of parathyroid cell growth by calcimimetics

Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism

Pharmacological properties of the calcimimetic compound NPS R-568 in vitro and in vivo

S38-5 Calcium receptor agonist (calcimimetics)：therapeutic potential in hyperparathyroidism

NPS R-568 halts or reverses osteitis fibrosa in uremic rats

Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Commentary

Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency

Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels

P2L-P13-2 Calcimimetics(cinacalcet HCI)suppress aortic and heart calcification in uremic rats

Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency

Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA®)

P3L-20 Effect of manipulating serum phosphorus with sevelamer hydrochloride, a phosphate binder, on circulating parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) levels in rats with chronic renal insufficiency

Suchergebnisse filtern